Cargando…
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression is associated with hypoxia and the induction of hypoxia-inducible factor (HIF). Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies. However,...
Autores principales: | Zhou, Yinghong, Dong, Xiaofeng, Xiu, Peng, Wang, Xin, Yang, Jianrong, Li, Lei, Li, Zhongchao, Sun, Pengfei, Shi, Xuetao, Zhong, Jingtao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128048/ https://www.ncbi.nlm.nih.gov/pubmed/32273947 http://dx.doi.org/10.1155/2020/7079308 |
Ejemplares similares
-
Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells
por: Zhong, Jingtao, et al.
Publicado: (2018) -
T7 peptide cytotoxicity in human hepatocellular carcinoma cells is mediated by suppression of autophagy
por: Liu, Feng, et al.
Publicado: (2019) -
Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways
por: Dong, Xiaofeng, et al.
Publicado: (2014) -
Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam
por: Curtiss, Frederic R.
Publicado: (2006) -
Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide in vitro and in vivo
por: Yang, Jianrong, et al.
Publicado: (2021)